Once China takes action in the "medical field", the United States will not even have the confidence to refute it!

From 2017 to 2025, a full eight years, from Trump's stay in the White House to his return to the White House, the only thing that remains unchanged in U.S. foreign policy seems to be the "tariff war." This abnormal international relationship is becoming very "normal".

In the end, the United States suffered a backlash. Because last year, China's export control measures on rare earths were taken as the dividing line, China has become more and more familiar with the issue of countering the tariff hegemony of the United States. It can be said that it has hit the weakest place of the United States.

On October 9, China successively strengthened export controls on rare earths and imposed special port fees on merchant ships owned, held, operated by the United States and flying the U.S. flag.

On October 11th, Trump proposed to "increase tariffs". One day later, the US stock market plummeted, and he had to euphemistically excuse himself, saying that he was only good for China.

On the one hand, the words hit the Chinese neck, while in the actual action, being hit by the Chinese neck, Trump vowed to practice "win" to the end, only to break the teeth into the stomach and swallow.

However, just as Trump focused on the rare-earth issue, China uncovered another killer trap in his hands.

On October 15, the US media The New York Times released a report stating that half of the more than 700 kinds of pharmaceutical raw materials imported by the United States rely on Chinese exports. For every 1% increase in tariffs, corporate profits will decrease by 2%. This is also against the background of the United States' initiative to impose tariffs.

From importing raw materials to exporting finished drugs, tariffs are superimposed, and drug profits will be directly pressed to the lowest point, and pharmaceutical companies will have nowhere to go.

This is even against the background of Trump's additional tariffs, and American pharmaceutical companies are complaining endlessly. However, if China takes action in this area, or even applies export controls on rare earths to pharmaceutical raw materials, the U.S. pharmaceutical industry may collapse.

China has become one of the world's largest producers of drug raw materials, India's imitation drug development momentum is good, and the raw materials still come from China.

In penicillin and enzyme synthesis technology, only three companies in the world can produce, while China occupies two.

After 2016, the United States launched a tariff war, the government "subsidized" all industries, greatly promoted the development of all industries, and pharmaceutical companies were more rapidly advancing.

From raw materials to finished medicines and innovative medicines, China has become a major power in raw materials and medicine.

The United States also has its own industrial chain. Affected by high environmental protection requirements, the local wastewater treatment price is US $2.8 per ton, which is three times higher than that in China. This directly stifles their possibility of developing local medicine in large quantities.

In April 2025, Trump released a list of "additional tariffs" on drugs.

Less than a month later, the government announced an order to delay the collection of drug tariffs because local pharmaceutical companies were affected, and almost all U.S. drug brand manufacturers were protesting against the government.

More than 90% of pharmaceutical companies in the United States are late-stage manufacturers and are only responsible for technical updates. More raw materials and semi-finished products come from China and India. The quality of Indian products is uneven, and they prefer to cooperate with China.

Moreover, China exports to India, then from India to the United States, in the meantime, will increase costs, transportation costs, the US pharmaceutical companies are not willing to bear this part of the surplus costs.

As the Tobin said, controlling technology and military-based materials is now just an appetizer.

The real trump card is actually the pharmaceutical industry. Once the supply of raw materials is affected, the 22 American pharmaceutical companies on the Fortune list will face drug shortages, and the remaining small pharmaceutical companies will also indirectly go bankrupt.

The United States has no production technology or conditions for pharmaceutical raw materials, so it can only rely on external procurement. China's control will only completely paralyze the American economy, and the masses will even look down on diseases.

If China discontinues its supply of chemical raw materials, cancer chemotherapy will be disrupted, which will have a huge impact on the local pharmaceutical system.

Trump will only criticize China with a tougher attitude after feeling a failure, but will be forced to decline in the economy and will briefly "stop the war".

In this huge game, Trump refused to admit defeat, but had to admit defeat.

Especially the recent "government shutdown" is not over yet, tens of thousands of people's wages can't be paid, and the number of real government officials will decrease, which makes him even more panicked.

The more at this time, his actions against the Chinese side will be more violent, but the core of the negotiations is not on the US side, every time they are forced to "negotiate with the Chinese side".

Dean Wang Wen once said, don't be afraid of the "pressure" of the United States. China's counter-measures have advantages and will eventually bring them back to the negotiation table.

So far, the United States has more than 3000 control lists on China, which has not brought substantial pressure on China.

Looking at the current contrast between the two sides, China's foreign export controls have only more than 900 items, but have caused their military industry and technology to collapse repeatedly, and the stock price has fallen repeatedly.

In order not to buy U.S. soybeans, directly bankrupt soy farmers, the government had to promise to export and give subsidies.

However, the government is still in chaos, and it is unknown when the subsidies will be in place.

Conclusion:

Since April 8, the U.S. government has carried out several "out-of-the-counter" actions against Chinese medicine, and after increasing the tariff proposal, local enterprises have been forced to rebel and have to stop.

To raise tariffs again in October, again affecting the industry, just as unsuccessful.

Every time, Trump swaggered to bring down China, and as a result, he plunged himself into crisis.

Moreover, once he successfully imposes tariffs, the ones who will suffer the most will be U.S. companies. If they don't sell them to the United States, China can also sell them to Europe, Latin America, the Middle East and other places. If the United States does not use China's raw materials, it will only get into trouble.